Review of biomarkers in systemic juvenile idiopathic arthritis: Helpful tools or just playing tricks?

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Gohar, Faekah ^a   Kessel, Christoph ^a   Lavric, Miha ^a   Holzinger, Dirk ^a   Foell, Dirk ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN C; HEME OXYGENASE 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; OSTEOPROTEGERIN;

ARTICLE; COHORT ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE ACTIVITY; HUMAN; MACROPHAGE ACTIVATION SYNDROME; PROGNOSIS; SYSTEMATIC REVIEW; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT OUTCOME; ARTHRITIS, JUVENILE;

ARTHRITIS, JUVENILE; BIOMARKERS; HUMANS;

EID: 84979513588     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1069-z     Document Type: Article

References (113)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur A, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31;390-92. http://www.jrheum.org/content/31/2/390.citation.
2. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71(9):1437-9.
3. Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-15.
4. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56(11):3793-804.
5. Macaubas C, Nguyen KD, Peck A, Buckingham J, Deshpande C, Wong E, et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol. 2012;142(3):362-72.
6. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479-86.
7. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416-26.
8. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11(5):290-300.
9. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther. 2008;10(3):208.
10. Tektonidou MG, Ward MM. Validation of new biomarkers in systemic autoimmune diseases. Nat Rev Rheumatol. 2011;12:708-17.
11. Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol. 2013;147(3):229-41.
12. Duurland CL, Wedderburn LR. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Curr Rheumatol Rep. 2014;16(3):406.
13. Consolaro A, Varnier GC, Martini A, Ravelli A. Advances in biomarkers for paediatric rheumatic diseases. Nat Rev Rheumatol. 2015;11(5):265-75.
14. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013;9(5):267-76.
15. Oldenhuis CNAM, Oosting SF, Gietema JA, de Vries EGE. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946-53.
16. Søreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol. 2009;62(1):1-5.
17. Holzinger D, Frosch M, Kastrup A, Prince FHM, Otten MH, Van Suijlekom-Smit LWA, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(6):974-80.
18. Lau TYK, Power KA, Dijon S, Gardelle I De, Mcdonnell S, Duffy MJ, et al. Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification research articles. J Proteome Res. 2010;9(3):1450-9.
19. Bae CB, Suh CH, An JM, Jung JY, Jeon JY, Nam JY, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset still's disease. J Rheumatol. 2014;41(12):2403-8.
20. Nirmala N, Grom A, Gram H. Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes. Curr Opin Rheumatol. 2014;26(5):543-52.
21. Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;66(6):949-55.
22. Cangemi G, Pistorio A, Miano M, Gattorno M, Acquila M, Bicocchi MP, et al. Diagnostic potential of hepcidin testing in pediatrics. Eur J Haematol. 2013;90(4):323-30.
23. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA Am Med Assoc. 2010;303(13):1266-73.
24. Lotito APN, Campa A, Silva CAA, Kiss MHB, Mello SBV. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol. 2007;34(4):823-30.
25. Jelusić M, Lukić IK, Tambić-Bukovac L, Dubravcić K, Malcić I, Rudan I, et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol. 2007;26(8):1332-4.
26. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345-8.
27. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-95.
28. Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, Banchereau J. How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev. 2008;223:39-59.
29. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol (Hoboken, NJ). 2014;66(4):1034-43.
30. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-406.
31. Butterfield L, Whiteside T. Cytokine Assays. Chichester: John Wiley & Sons, Ltd; 2016. p. 1-11. eLS.
32. Gaines Das RE, Poole S. The international standard for interleukin-6. J Immunol Methods. 1993;160(2):147-53.
33. Ledur A, Fitting C, David B, Hamberger C, Cavaillon J-M. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J Immunol Methods. 1995;186(2):171-9.
34. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011;2011:815038.
35. Gibson DS, Rooney ME, Finnegan S, Qiu J, Thompson DC, Labaer J, et al. Biomarkers in rheumatology, now and in the future. Rheumatology (Oxford). 2012;51(3):423-33.
36. Hügle B, Hinze C, Lainka E, Fischer N, Haas J-P. Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. Pediatr Rheumatol Online J. 2014;12(1):28.
37. Shin JI, Kim KH, Chun JK, Lee TJ, Kim KJ, Kim HS, et al. Prevalence and patterns of anti-nuclear antibodies in Korean children with juvenile idiopathic arthritis according to ILAR criteria. Scand J Rheumatol. Informa UK Ltd UK. 2008;37(5):348-51.
38. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.
39. Gilliam BE, Chauhan AK, Low JM, Moore TL. Pediatric rheumatology. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol. 2008;26(3):492-7.
40. Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S, et al. Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J. 2014;12:22.
41. Cummings J, Raynaud F, Jones L, Sugar R, Dive C. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer. 2010;103(9):1313-7.
42. Swan AL, Stekel DJ, Hodgman C, Allaway D, Alqahtani MH, Mobasheri A, et al. A machine learning heuristic to identify biologically relevant and minimal biomarker panels from omics data. BMC Genomics. 2015;16 Suppl 1:S2.
43. Anderson NGL, Anderson NGL. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845-67.
44. Solé X, Crous-Bou M, Cordero D, Olivares D, Guinó E, Sanz-Pamplona R, et al. Discovery and validation of new potential biomarkers for early detection of colon cancer. PLoS One. 2014;9(9):e106748.
45. Ling XB, Park JL, Carroll T, Nguyen KD, Lau K, Macaubas C, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics. 2010;10(24):4415-30.
46. STRING: functional protein association networks [Internet]. [cited 2016 Jan 7]. Available from: http://string-db.org/. Accessed 27 July 2016.
47. van den Ham H-J, de Jager W, Bijlsma JWJ, Prakken BJ, de Boer RJ, Van Den Ham H, et al. Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford). 2009;48(8):899-905.
48. Eng SWM, Duong TT, Rosenberg AM, Morris Q, Yeung RSM. The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66(12):3463-75.
49. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh Ch, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Eng J Med. 2006;355(25):2631-9.
50. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415-24.
51. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(12):1794-803.
52. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635.
53. Bakker MF, Cavet G, Jacobs JW, Bijlsma JWJ, Haney DJ, Shen Y, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012;71(10):1692-7.
54. Michaud K, Strand V, Shadick NA, Degtiar I, Ford K, Michalopoulos SN, et al. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology (Oxford). 2015;54(9):1640-9.
55. Segurado OG, Sasso EH. Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(Suppl. 85):S29-S34.
56. Smith E, Oni L, Midgley A, Ekdawy D, Corkhill R, Jones C, et al. Demonstration of an "excellent" biomarker panel for identifying active lupus nephritis in children. Ann Rheum Dis. 2015;331.
57. de Jager W, Hoppenreijs EPAH, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66(5):589-98.
58. De Jager W, Velthuis H, Prakken BJ, Rijkers GT, Kuis W. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10(1):133-9.
59. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use-a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl. 2010;4(12):892-903.
60. Gillio-Meina C, Cepinskas G, Cecchini EL, Fraser DD. Translational research in pediatrics II: blood collection, processing, shipping, and storage. Pediatrics. 2013;131(4):754-66.
61. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009;10(1):52.
62. Van den Bruel A, Cleemput I, Aertgeerts B, Ramaekers D, Buntinx F. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol. 2007;60(11):1116-22.
63. Gibson DS, Finnegan S, Pennington S, Qiu J, LaBaer J, Rooney ME, Duncan MW. Chapter 8: Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders. In: Huang F-P, editor. Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights. InTech; 2011. p. 614. ISBN 978-953-307-653-9. doi: 10.5772/1851.
64. Hunter DJ, Losina E, Guermazi A, Burstein D, Lassere MN, Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets. 2010;11(5):536-45.
65. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312-28.
66. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol (Hoboken, NJ). 2014;66(6):1405-13.
67. McArdle A, Butt AQ, Szentpetery A, Jager W De, Roock S de, FitzGerald O, et al. Technical brief. Developing clinically relevant biomarkers in inflammatory arthritis: a multi-platform approach for serum candidate protein discovery. Proteomics Clin Appl. 2015;1-20.
68. Simonini G, Matucci Cerinic M, Cimaz R, Anichini M, Cesaretti S, Zoppi M, et al. Evidence for immune activation against oxidized lipoproteins in inactive phases of juvenile chronic arthritis. J Rheumatol. 2001;28(1):198-203.
69. El-Sayed ZA, Saleh MT, Al-Wakkad AS, Sherief LS, AM N e-D. Cartilage proteoglycan aggrecan as a predictor of joint damage in juvenile rheumatoid arthritis. East Mediterr Health J. 2001;7(6):992-1003.
70. Bloom BJ, Toyoda M, Petrosian A, Jordan S. Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis. Rheumatol Int. 2007;27(7):655-60.
71. Bodman-Smith MD, Fife MF, Wythe H, Corrigal VM, Panayi GS, Wedderburn LR, et al. Anti-BiP antibody levels in juvenile idiopathic arthritis (JIA). Rheumatology (Oxford). 2004;43(10):1305-6.
72. Ozawa R, Inaba Y, Mori M, Hara R, Kikuchi M, Higuchi R, et al. Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis. Mod Rheumatol. 2012;22(4):558-64.
73. Gheita TA, Bassyouni IH, Emad Y, el-Din AMN, Abdel-Rasheed E, Hussein H. Elevated BAFF (BLyS) and APRIL in juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity. Joint Bone Spine. 2012;79(3):285-90.
74. Kounami S, Yoshiyama M, Nakayama K, Okuda M, Okuda S, Aoyagi N, et al. Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol. 2005;113(2):124-9.
75. Simonini G, Azzari C, Gelli AMG, Giani T, Calabri GB, Leoncini G, et al. Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients. Rheumatol Int. 2005;25(5):336-40.
76. Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M, Silvia Q. Pediatric rheumatology. Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26(2):373-8.
77. Nakajima S, Naruto T, Miyamae T, Imagawa T, Mori M, Nishimaki S, et al. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2009;19(1):42-6.
78. Urakami T, Manki A, Inoue T, Oda M, Tanaka H, Morishima T. Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis. J Rheumatol. 2006;33(5):996-1000.
79. Bloom BJ, Alario AJ, Miller LC. Persistent elevation of fibrin D-dimer predicts long term outcome in systemic juvenile idiopathic arthritis. J Rheumatol. 2009;36(2):422-6.
80. Wilson DC, Marinov AD, Blair HC, Bushnell DS, Thompson SD, Chaly Y, et al. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2510-6.
81. Gorelik M, Fall N, Altaye M, Barnes MG, Thompson SD, Grom AA, et al. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2013;40(7):1191-9.
82. Karagiozoglou-Lampoudi T, Trachana M, Agakidis C, Pratsidou-Gertsi P, Taparkou A, Lampoudi S, et al. Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity. Metabolism. 2011;60(10):1359-62.
83. Bobek D, Grčević D, Kovačić N, Lukić IK, Jelušić M. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J. 2014;12(1):50.
84. Takahashi A, Mori M, Naruto T, Nakajima S, Miyamae T, Imagawa T, et al. The role of heme oxygenase-1 in systemic-onset juvenile idiopathic arthritis. Mod Rheumatol. 2009;19(3):302-8.
85. Shimizu M, Yachie A. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages. Cytokine. 2012;60(1):226-32.
86. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology. 2015;54(8):1507-17.
87. Ferreira RA, Silva CHM, Silva DAO, Sopelete MC, Kiss MHB, Mineo JR, et al. Is measurement of IgM and IgA rheumatoid factors (RF) in juvenile rheumatoid arthritis clinically useful? Rheumatol Int. 2007;27(4):345-9.
88. Shahin AA, Shaker OG, Kamal N, Hafez HA, Gaber W, Shahin HA. Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography. Rheumatol Int. 2002;22(2):84-8.
89. Yilmaz M, Kendirli SG, Altintas D, Bingöl G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol. 2001;20(1):30-5.
90. Chen O, Shan N, Zhu X, Wang Y, Ren P, Wei D, et al. The imbalance of IL-18/IL-18BP in patients with systemic juvenile idiopathic arthritis. Acta Biochim Biophys Sin Shanghai. 2013;45(4):339-41.
91. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49(9):1645-53.
92. Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum. 2002;46(9):2539-41. author reply 2541-2.
93. Aggarwal A, Agarwal S, Misra R. Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA). Clin Exp Immunol. 2007;148(3):515-9.
94. Ezzat MHM, El-Gammasy TMA, Shaheen KYA, Osman AOY. Elevated production of galectin-3 is correlated with juvenile idiopathic arthritis disease activity, severity, and progression. Int J Rheum Dis. 2011;14(4):345-52.
95. Bica BERG, Gomes NM, Fernandes PD, Luiz RR, Koatz VLG. Nitric oxide levels and the severity of juvenile idiopathic arthritis. Rheumatol Int. 2007;27(9):819-25.
96. Sarma PK, Misra R, Aggarwal A. Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol. 2008;27(3):289-94.
97. Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, et al. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol. 2009;36(10):2308-13.
98. Tomoum HY, Mostafa GA, El-Shahat EMF. Autoantibody to heterogeneous nuclear ribonucleoprotein-A2 (RA33) in juvenile idiopathic arthritis: clinical significance. Pediatr Int. 2009;51(2):188-92.
99. Gheita TA, El-Gazzar II, El Shazly RI, El-Din AMN, Abdel-Rasheed E, Bassyouni RH. Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity. J Clin Immunol. 2013;33(1):297-301.
100. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004;50(4):1286-95.
101. Shenoi S, Ou J-N, Ni C, Macaubas C, Gersuk VH, Wallace CA, et al. Comparison of biomarkers for systemic juvenile idiopathic arthritis. Pediatr Res International Pediatric Research Foundation, Inc. 2015;78(5):554-9.
102. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924-31.
103. Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(3):883-91.
104. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965-71.
105. Singh A, Vastert SJ, Prakken BJ, Illges H. Decreased levels of sCD21 and sCD23 in blood of patients with systemic-juvenile arthritis, polyarticular-juvenile arthritis, and pauciarticular-juvenile arthritis. Rheumatol Int. 2012;32(6):1581-7.
106. Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr. 2013;162(6):1245-51.
107. Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int J Rheum Dis. 2014;17(3):261-7.
108. Chen C, Tsao C, Ou L, Yang M, Kuo M, Huang J. Comparison of soluble adhesion molecules in juvenile idopathic arthritis between the active and remission stages. Ann Rheum Dis. 2002;61:167-70.
109. De Benedetti F, Vivarelli M, Pignatti P, Oliveri M, Massa M, Pistorio A, et al. Circulating levels of soluble E-selectin, P-selectin and intercellular adhesion molecule-1 in patients with juvenile idiopathic arthritis. J Rheumatol. 2000;27(9):2246-50.
110. Bloom BJ, Nelson SM, Eisenberg D, Alario AJ. Soluble intercellular adhesion molecule-1 and E-selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis. J Rheumatol. 2005;32(2):366-72.
111. Ishikawa S, Shimizu M, Ueno K, Sugimoto N, Yachie A. Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis. Cytokine. 2013;62(2):272-7.
112. El-Gamal YM, Heshmat NM, El-Kerdany TH, Fawzy AF. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Allergy Immunol. 2004;15(3):270-7.
113. Muzaffer MA, Dayer J-M, Feldman BM, Pruzanski W, Roux-Lombard P, Schneider R, et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol. 2002;29(5):1071-8.